Trial record 2 of 5 for:    glycomimetics

Preventing Fucose-dependent Binding of Aspergillus and Pseudomonas to Lung Mucin (CADET)

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by University of California, San Francisco
Sponsor:
Information provided by (Responsible Party):
John V. Fahy, University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT01533636
First received: February 10, 2012
Last updated: September 3, 2014
Last verified: September 2014
  Purpose

The investigators will collect samples of sputum from healthy volunteers and patients with cystic fibrosis for the purpose of: a) purifying airway mucins for plate-based binding studies and; b) assessment of the effects of carbohydrates on the rheologic properties of the sputum.

This study has two hypotheses:

  1. Lectins from Pseudomonas aeruginosa and Aspergillus fumigatus bind to airway mucins in a fucose-dependent manner, and this binding can be inhibited by fucosyl glycomimetic compounds.
  2. Fucosyl glycomimetics will compete with Pseudomonas aeruginosa lectin (PA-IIL) and Aspergillus fumigatus lectin (AFL) and disrupt lectin-driven mucin cross-linking in CF sputum.

Condition
Cystic Fibrosis

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Preventing Fucose-dependent Binding of Aspergillus and Pseudomonas to Lung Mucin

Resource links provided by NLM:


Further study details as provided by University of California, San Francisco:

Primary Outcome Measures:
  • Mucus viscosity [ Time Frame: Up to one hour ] [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: July 2012
Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts
Healthy Control
Cystic Fibrosis

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Cystic Fibrosis and Healthy Controls

Criteria

Inclusion Criteria:

  • Healthy control subjects:

    • Age 18-65
    • No history of lung disease
  • Cystic fibrosis subjects:

    • Age 18-65
    • No history of lung disease other than cystic fibrosis
    • Diagnosis of CF if sweat chloride values > 60 mM on two separate pilocarpine iontophoresis sweat tests and/or two allelic CF-producing mutations in genetic analysis

Exclusion Criteria:

  • Use of recreational drugs within 30 days prior to enrollment
  • Use of tobacco within 30 days prior to enrollment, or > 10 pack-year tobacco history
  • Pregnant or lactating females
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01533636

Contacts
Contact: Kelly Norsworthy, BA 415-502-8791 kelly.norsworthy@ucsf.edu

Locations
United States, California
University of California, San Francisco Recruiting
San Francisco, California, United States, 94143
Contact: Kelly Norsworthy, BA    415-502-8791    kelly.norsworthy@ucsf.edu   
Sponsors and Collaborators
University of California, San Francisco
Investigators
Principal Investigator: John V Fahy, MD University of California, San Francisco
  More Information

No publications provided

Responsible Party: John V. Fahy, Professor in Residence, University of California, San Francisco
ClinicalTrials.gov Identifier: NCT01533636     History of Changes
Other Study ID Numbers: 10-04834
Study First Received: February 10, 2012
Last Updated: September 3, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by University of California, San Francisco:
Cystic Fibrosis, Healthy

Additional relevant MeSH terms:
Cystic Fibrosis
Fibrosis
Digestive System Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Lung Diseases
Pancreatic Diseases
Pathologic Processes
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on October 30, 2014